List of Antibodies Companies in South Korea - 42

AbClon was founded in 2010 by a consortium of Korean and Swedish experts in antibody development. Our mission is to cure once incurable diseases such as cancer.

ABL Bio Inc. (Kosdaq: 298380) is a South Korean biotechnology company dedicated to the development of bispecific antibody therapeutics to improve and save people's lives. With our BsAb platforms ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B,’ we have built a robust pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated excellent efficacy and safety. We also created a next-generation antibody drug conjugate program to treat various cancers. In the neurodegenerative disorder space, we have developed Grabody-B platform, which is designed to maximize blood-brain barrier (BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. We continue to actively expand and advance our pipeline through global strategic partnerships. For more information, please visit http://ablbio.com

We aim to advance current state-of-the-art AI drug discovery technologies and transform high-cost, low-efficiency drug discovery practices into rapid, efficient discovery, ultimately leading to high success rates in the clinical phase. Our award-winning AI drug discovery platform enables the direct discovery of high potency drugs that induce desired cellular-level activity with minimal off-target effects and toxicity. AIGEN Sciences will revolutionize AI-based drug discovery.

ALTEOGEN Inc., Daejeon(fifth-largest metropolis)-based in South Korea, is a leading biopharmaceutical company with a leading edge pipeline of novel biologics such as next generation biobetters including long-acting therapeutic proteins, Antibody-Drug Conjugate (ADC) therapeutic antibodies and monoclonal antibody biosimilars. The company was founded in 2008 and listed in KOSDAQ stock market (KRX:196170). Our innovative NexP™ fusion technology is applied to various proteins and peptides to allow longer activities in human beings. Long-acting human Growth Hormone, long-acting exenatide (for diabetes) and long-acting Factor VIIa (for hemophilia) are developed with the NexP™ fusion technology. Our proprietary ADC technology, NexMab™ ADC technology is well suited for the targeted therapy for the cancer drugs with lower side effect and better efficacy. With this NexMab™ ADC technology, we are developing ADC therapeutics for breast/gastric cancer and ovarian cancer. Alteogen's mostly distinguished Hybrozyme™ technology to a human hyaluronidase, which has been widely used to improve the absorption of drug biologics delivered via subcutaneous injection. The novel human hyaluronidase based on Hybrozyme™ technology showed improved enzymatic activity and thermal stability. Based on long and rich experiences, Alteogen has quickly developed its own cell lines with high expression, efficient process (upstream and downstream), and optimized analysis methods for monoclonal antibody biosimilars including Herceptin preparing for the phase 3 trials upon completion of global phase 2 testing, SC formulation of Herceptin biosimilar as well as working on Eylea biosimilar.

APITBIO is a biotech company that specializes in antibody therapeutics research and development.

Biopharmaceutical company focused on developing and manufacturing biosimilar products, new protein drugs and bispecific antibodies

Art Blood Co., Ltd. is a company that is building/developing a cell-based in vitro blood production system to solve the problem of blood for transfusion that is in short supply worldwide and has side effects. In addition, we are developing a platform to provide reagent red blood cells used to detect transfusion-related antibodies and therapeutic red blood cells that transport and express various therapeutic agents and immunostimulants.

Boditech Med Inc. has been developing products for in-vitro diagnostics and diagnostic reagents for the past 20 years by pursuing the value of a company called "Respect for Life"​. In particular, about 60,000 units of ichroma ™ readers are installed and operated world wide, and ichroma™ CRP (C-Reactive Protein) has secured its largest market share in China, showing a unique competitiveness. Boditech Med Inc. is leading the way in exploring new markets through the automation of on-site diagnosed immunodiagnostic devices and the development of new high-sensitive diagnostic reagents. We have built up our reputation successfully by carrying out various national R & D projects based on solid technology, experience, and human resources accumulated over the years. In addition, Boditech Med Inc. is developing a smart production system that integrates digital technology and IT technology to flexibly manage the production scale. All employees of Boditech Med Inc. is making every effort with pride that we are the top leader of BT-IT convergence industry in Korea.

CanariaBio is a biopharmaceutical company that focuses on developing and commercializing immunotherapies for cancer, utilizing a technology platform of tumor antigen specific monoclonal immunoglobulins targeting CA-125, MUC1, PSA and Her2/neu.

Celltrion is a leading biopharmaceutical company that specializes in research, development and manufacturing of innovative therapeutics. We are committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. We have been at the forefront of biotherapeutic development uncovering new ways of targeting the drivers of disease by creating next-generation biologics and small molecule products. For additional information on our guidelines, please visit: http://tinyurl.com/bdh9bxs9

Eutilex is a KOSDAQ listed company that researches and develops new drugs with a focus on immunotherapy

Genome & Company is a global pharmaceutical bio company that focuses on research and development of microbiome medicines and new drug targets ('targets')-based immunotherapy agents based on abundant clinical data and multi-omics technology (Multi-Omics). Since its establishment in 2015, Genome & Company has been a global leader in the field of microbiome immuno-oncology drugs and new target immuno-oncology drugs, implementing the 'Bed-to-Bench' strategy (clinical data-based research) of GNOCLE™, an independent drug candidate discovery platform. Development Strategy), we have collaborated with major domestic and foreign pharmaceutical and bio companies and research-oriented hospitals. In the future, Genome & Company will not only accelerate the development of innovative treatments for high unmet medical needs by utilizing the microbiome and new drug targets, but will also strengthen its production and commercialization capabilities to become a fully integrated pharmaceutical bio company.

Founded in 2016 in South Korea, Genuv(지뉴브) is a clinical-stage biopharma that specializes in discovering and developing innovative therapeutics based on own platform technologies for drug discovery. GENUV is dedicated to the discovery and development of life-transforming therapeutics for patients with debilitating diseases. To do this, we passionately endeavor to advance our own platform technologies and capitalize on our strengths in multi-disciplinary collaborations with external partners. Our current research and development focus is on a) small molecule drugs to treat neurodegenerative diseases through neurogenesis and neural homeostasis and b) antibody drugs for immuno-oncology treatment.

Biologics, Small Molecules

Hanmi Pharmaceutical, Co., Ltd., headquartered in Seoul, South Korea, and established in 1973, has become one of the largest companies not only in Korea but also within the region, selling over 200 products worldwide. Today, Hanmi is also recognized as the No.1 R&D investing company in Korea, spending over 10~15% of the company’s annual revenue in developing next generation Platform Technologies & NCE products.

Helixmith is a gene therapy company headquartered in Seoul, Korea, developing new and innovative biopharmaceuticals for previously untreated diseases, and is listed on KOSDAQ. The company has an extensive gene therapy pipeline, including a CAR-T program targeting several different types of solid tumors and an AAV vector program targeting neuromuscular diseases. Engensis (VM202), a more advanced pipeline candidate, is a plasmid DNA therapy being studied for DPN, diabetic foot ulcers, claudication, amyotrophic lateral sclerosis (Phase 2 beginning in late 2020), coronary artery disease and Charcot-Marie-Tooth disease. Helixmith clinical development activities are based in San Diego, California,

At ILIAS Biologics, we dedicate ourselves to the paradigm-shifting advances in human medicine. We are specialized in developing engineered exosomes by loading large therapeutic payloads inside exosomes via our proprietary platform technology, EXPLOR®. By harnessing the power of our engineered exosomes, we can deliver therapeutic proteins to the undruggable intracellular pathways to treat life-threatening and hard-to-treat rare diseases. With a strong belief and the power of open innovation, we are expanding our global network of research and business alliances to maximize our potential in the development of the novel exosome platform technology.

Clinical-stage Biopharmaceutical Company developing burfiralimab against Chronic hepatitis B and autoimmune diseases. Also Antibodies and small molecules are in the pipeline for oncological and immunological disorders.

ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan and Sorrento, ImmuneOncia will leverage both companies’ expertise in drug development and antibody engineering. Our mission is to bring safe, effective, and novel immunotherapies to oncology patients world-wide. ImmuneOncia’s portfolio includes diverse immune checkpoint antibodies; the lead antibody IMC-001 Phase I study was completed in Feb 2019 and its Phase 2 study is being prepared. ImmuneOncia is also developing several antibodies targeting novel immune-checkpoints.

InnobationBio Co., Ltd., headquartered in the Republic of Korea, is a biotechnology company having established two major platforms. Its R&D capabilities are utilized to develop antibody and cell immunotherapy for cancer treatment, as well as liquid biopsy-based biomarkers.

ISU ABXIS is continuously striving to provide better treatment options for patients suffering from difficult-to-treat diseases based on Isu’s excellence in biotechnology.

Kanaph Therapeutics is developingtherapeutics for oncology by using bi-specific antibodies and small molecules that have a greatly enhanced immuno-stimulatory activity in the tumor micro-environment (TME).

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to the discovery, development, and commercialization of innovative medicines by leveraging our chemistry expertise to make conventional biologics more targeted and potent for the benefit of patients with diseases of highly unmet medical needs. We are advancing sustainable pipelines in therapeutic areas within antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).

LigaChem Biosciences (formerly LegoChem Biosciences, Inc.) is a clinical stage biopharmaceutical company focused on the development of novel therapeutics utilizing its proprietary drug delivery technologies and therapeutic antibodies. The company's pipeline includes antibody-drug conjugates (ADCs) and immuno-oncology therapeutics for the treatment of cancer and other serious diseases. LigaChem Biosciences is headquartered in Daejeon, South Korea, with additional offices in Seoul. The company has entered into co-development and license agreements for its ADC programs and has completed acquisitions by other companies. LigaChem Biosciences is committed to advancing innovative treatments for patients in need.

Headquartered in Seoul, South Korea, LOTTE BIOLOGICS was founded in 2022 with a mission to deliver therapies that contribute to a healthier world. At the Syracuse Bio Campus in New York, LOTTE BIOLOGICS provides high-quality GMP manufacturing services for drug substances. The facility offers a total production capacity of 40,000L, supported by eight 5,000L stainless steel bioreactors. Additionally, the campus includes extensive analytical QC testing laboratories and warehouse facilities that have received approval from over 62 regulatory agencies worldwide. LOTTE BIOLOGICS is also advancing into a new area of expertise with Antibody-Drug Conjugates (ADCs) conjugation services, expected to be fully operational by early 2025. With over $80 million invested in ADC modalities, including both drug substance and conjugation capabilities on-site, we offer a seamless, end-to-end service from drug substance manufacturing to conjugation. Looking ahead to 2030, LOTTE BIOLOGICS is constructing three advanced bio plants in Songdo, South Korea. With construction of the first plant already underway and expected to be operational by 2026, each facility will feature eight 15,000L stainless steel bioreactors for large-scale commercial production, along with multiple 2,000L single-use bioreactors to meet clinical production needs. Collectively, these plants will provide a manufacturing volume exceeding 360,000L in bioreactor capacity. Through our commitment to delivering innovative medicines to patients worldwide, LOTTE BIOLOGICS aims to become a Global Top 10 CDMO company in the biopharmaceutical industry.

Over the past decades, focusing on a battery of conventional genes/proteins involved in the neurodegeneration has been disappointing in the field of neurodegenerative therapeutics. With the scientific responsibility and integrity, Neuracle Science is a clinical stage biotech company specialized in the development of breakthrough therapies for those who are living with serious and devastating neurodegenerative diseases. We provide a foundation for disease-modifying treatments for neurodegenerative diseases, discovering a completely novel and invaluable gene/protein target with unknown significance using non-biased study. Neuracle Science is based in Seoul, South Korea. We were founded in 2015 by scientific leaders in neuroscience, bioinformatics-based drug discovery, GPCR-mediated signaling, and antibody drug.

Novelty Nobility Inc. is a private clinical stage biotech company located in Pangyo, South Korea, and Boston, Massachusetts. We are currently focused on the research of novel angiogenesis targets and develop antibody-based therapeutics in ophthalmology and oncology, where angiogenesis plays a key pathogenic role. Novelty Nobility, a unique name for a biotech company, stands for what we pursue – Novel Science, Noble Management. The emblem in the middle of our logo, which shapes a drug, symbolizes our belief that a new drug is born when novel science meets noble management.

Panolos Biosciences is at the forefront of structure-based protein design, ceaselessly pushing the limits of multi-specific drug development. We are dedicated to the creation of anti-angiogenic therapies for the treatment of cancer, autoimmune, and rare diseases. Our unique patented technology, "Alpha(α)-ART (Anti-angiogenesis-based Artifact Re-targeting Tri-specific)", employs a VEGF receptor backbone to develop mono or multi-specific antibody therapeutics, amplifying their potency.

Established in 1997, Peptron focuses on platform technology and clinical developments. Referred to as "Cozy-Cure," Peptron's highest priority is promoting and promising the best quality of life for patients with better treatment options, compliance, and price advantage. Peptron members' expertise in drug discovery and research, business development and strategic planning, drug delivery and formulation, GMP production, and Quality Control has helped develop peptide-based platform technology, SmartDepot™. SmartDepot™ brings the initial research process to the final medication development and successful commercialization phase with superior competitiveness. In line with proprietary technologies, we develop sustained-release (SR) medications to extend the release profile of the drug from weekly to monthly. Further, Peptron values global CDMO business. In the last few years, we have successfully formulated working with global companies with our in-depth expertise and resources. Peptron can work with you to achieve formulation development, regulatory approval and commercial manufacturing.

PharmAbcine is a clinical stage public company developing next generation IgG based therapeutics to treat cancer, neovascular eye diseases, and vascular related unmet needs. PharmAbcine has its own HuPhage library and innovative selection system. This technology provides therapeutic antibodies for a wide spectrum of indications in oncology, immuno-oncology, ophthalmology, pulmonology etc. PharmAbcine's advanced 3G expression system accommodates high levels of antibody production and steady reproducibility. With these cutting-edge technology platforms, it provides state of the art antibody generation services. PharmAbcine has focused on the development of novel antibody therapeutics since the company’s foundation in 2008 and laid the groundwork for the commercialization of Olinvacimab, PMC-309, PMC-403, and PMC-402. We will also become an innovative global biotech company through the development of other new candidates such as PMC-005BL, PMC-122, PMC-401, and PMC-401s.

We are a biotech company developing new treatments for patients resistant to existing therapies based on innovative new drug modalities such as antibody-drug conjugate(ADC). Based on our strong R&D capabilities, we have built our next-generation ADC platform PINOT-ADC™ independently and have been working with various partners to research new ADC anticancer treatments. In addition, clinical development and commercialization of NTX-301, a targeted anticancer drug for blood/solid cancer, and NTX-101, a treatment for glaucoma, are underway.

Prestige Biologics Co., Ltd is a biopharmaceutical CMO, CDMO, CDEMO (Contract Development Engineering Manufacturing Organization) that provides complete solutions to the development and manufacturing requirements in your drug discovery from early stage to product registration and commercialization. Based on our fully established antibody drug & vaccine manufacturing capabilities, we now offer our upgraded CDMO service, CDEMO in which we provide customized engineering solutions for your manufacturing process in a customized manufacturing suite speed-built with our proprietary technology, ALITA Smart BioFactory™.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, endocrinology, hematology and nephrology. For more information, please visit: www.samsungbioepis.com. To see our community guidelines, please visit: bit.ly/2l0yiI3

Samsung Biologics is a fully integrated CDMO offering state-of-the-art contract development and manufacturing services. With proven regulatory approvals, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide.

Selecxine is a biopharmaceutical development company specialized in the field of immunotherapeutics. Selecxine strives to develop immunotherapeutics – a new paradigm of pharmaceuticals– through a specialized antibody development process, using an innovative platform technology of functional antibody screening and development. We endeavor to improve the survival rate and quality of life of cancer patients by developing anti-cancer immunotherapeutics that selectively stimulate the immune cells. These agents act against tumor cells through the regulation of cytokine function, which plays a key role in the enter cell activities. Based on our technology and expertise in the pharmacology and development field, we aim to provide safe and efficient therapeutics and innovative solutions for next-generation pharmaceuticals.

Shaperon is a clinical stage biotech company developing novel inflammasome inhibitors(small molecule). Its unique mechanism of action of GPCR-regulated P2X7 inhibition suppresses a broad spectrum of inflammatory cytokines including IL-1β, IL-18, IL-6, and TNF-α, etc. by controlling both priming and activation phase of inflammasome, whereas conventional approaches are designed to suppress only the activation phase. With this unique and novel modality which is best suited to address complex immune-mediated inflammatory disorders, we are currently developing multiple clinical programs in atopic dermatitis, cytokine release syndrome, Alzheimer’s disease, ulcerative colitis, NASH, etc. In addition to inflammasome R&D programs, Shaperon has anti-viral, anti-cancer nanobody therapeutics. Shaperon’s proprietary immunized nanobody libraries combined with high throughput screening and in vitro/in vivo system enable us to fast forward the realization of advantages of Nanobodies over conventional antibody-based medicines. We currently developing multi-valent, multi-specific Nanobodies in multiple delivery forms in oncology and viral infection diseases.

SillaJen Biotherapeutics, Inc. is located in San Francisco, one of the largest and most innovative biotech clusters in the world. Sillajen Biotherapeutics focuses on the research, development and manufacturing of oncolytic viruses to treat cancer; we are responsible for Clinical Operations, Regulatory Affairs, Research and Development, Manufacturing, Alliance Management and Accounting for clinical trials. SillaJen, Inc. is a South Korean based biotechnology company headquartered in Busan South Korea, with satellite offices in Seoul, South Korea and San Francisco, CA. The company is focused on the development and commercialization of oncolytic immunotherapy products using the SOLVETM platform, including its lead product Pexa-Vec, which is currently in Phase 3 trials for the treatment of advanced primary liver cancer. Additional information about SillaJen is available at www.sillajen.com.

TiumBio (KOSDAQ: 321550) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for patients with rare and incurable diseases. Our mission is to enhance the hope and happiness of humanity through scientific advancements. TiumBio currently has three leading pipeline assets in clinical trials, with TU2218 being investigated in Phase 2 and TU2670 and TU7710 in Phase 1. TU2218 is an oral immuno-oncology therapy targeting TGF-beta and VEGFR2, while TU2670 is an orally active non-peptide GnRH antagonist. Additionally, TU7710 is a bypass-factor treatment specifically designed for hemophilia patients who have developed neutralizing antibodies. TiumBio is located in Seongnam-si, South Korea and has three subsidiaries including Boston-based biotechnology company, Initium Therapeutics and a CDO compnay, Protium Science.

Wellmarker Bio is a spin-off company from Seoul Asan Medical Center(AMC), which is the largest and most renowned hospital in the Republic of Korea. We specialized in developing predictive biomarkers and first-in-class drugs through profound research know-hows and Research Institute that is comprised of Target discovery department, Drug discovery department, Medicinal chemistry department and CMC department.

Y-Biologics is Korea’s leading R&D biotech company in the field of antibody drug development. Since establishing Y-Biologics in 2007, our company has focused on the research and development of antibody therapeutics, successfully building two main platform technologies: Ymax®-ABL, a unique human antibody library, and ALiCE, a novel format for bispecific T-cell engager antibodies. Utilizing our excellent and differentiated platform technologies, we are striving to become a leading global antibody drug development company in the field of immuno-oncology. Here at Y-Biologics, with our full-cycle antibody development capabilities, we are pursuing full-fledged development of immuno-oncologic drugs using our bispecific antibody platform. We aim to address unmet medical needs by developing a next-generation immunotherapeutics with higher patient response rates and superior efficacy in comparison to existing immuno-oncology drugs. Y-SERVICE Technologys_Antibody Screening, Protein Expression, Cell Line Development, Analysis Service

Zymedi is a clinical-stage biopharmaceutical company focused on transforming the role of ARSs (Aminoacyl-tRNA Synthetases) as a novel target for discovering and developing treatments for serious, life-threatening conditions lacking effective therapies or standard care. Our lead asset, ZMA001, is a first-in-class therapeutic that targets Lysyl-tRNA synthetase 1 (KARS1). By controlling monocyte and macrophage infiltration to inhibit inflammation in pulmonary blood vessels, ZMA001 is being developed as a treatment for pulmonary arterial hypertension (PAH). Currently in Phase I trials through a CRADA with the U.S. NIH, ZMA001 shows promise in addressing the root causes of PAH, a market projected to reach $9.7 billion by 2028.